SOURCE: Barrier Therapeutics, Inc.

February 21, 2006 08:00 ET

Barrier Therapeutics to Release Fourth Quarter and Year-End 2005 Financial Results on February 27, 2006

Company to Host Conference Call at 4:30 p.m. ET on February 27, 2006

PRINCETON, NJ -- (MARKET WIRE) -- February 21, 2006 -- Barrier Therapeutics, Inc. (NASDAQ: BTRX), a pharmaceutical company developing and commercializing products in the field of dermatology, is scheduled to release financial results for the fourth quarter and year-end of 2005, on Monday, February 27, 2006 at approximately 4:00 p.m. Eastern Time. The Company will sponsor a conference call on February 27th at 4:30 p.m. Eastern Time to provide a company update and discuss the financial results for the quarter and year-end. Interested investors can listen to the call live over the Internet in the investor relations section of the Company's website located at or by dialing 1-866-425-6195 (U.S.) or 1-973-935-2981 (International) and using conference ID code: 7066949.

What:    Barrier Therapeutics, Inc. Fourth Quarter and Year-End 2005
         Corporate Update and Financial Results Conference Call

When:    Monday, February 27, 2006, 4:30 p.m. Eastern Time

Where:   The investor relations section of the Company's website
         located at

How:     Live over the Internet -- Simply log on to the web at the
         address above, or dial 1-866-425-6195 (U.S.) or 1-973-935-2981
        (International) and use conference ID code: 7066949.
Barrier Therapeutics, Inc. is a pharmaceutical company focused on the discovery, development and commercialization of pharmaceutical products in the field of dermatology. In addition to Vusion™ (0.25% miconazole nitrate, 15% zinc oxide and 81.35% white petrolatum) Ointment, which recently received FDA approval for the treatment of diaper dermatitis complicated by candidiasis, the Company currently markets Solagé® (mequinol 2%, tretinoin 0.01%) Topical Solution in the U.S. and Canada for the treatment of solar lentigines, a common condition also known as "age spots," and markets VANIQA® (eflornithine hydrochloride) Cream 13.9% in Canada for the slowing of growth of unwanted facial hair in women. Barrier's Sebazole™ product candidate, for the treatment of seborrheic dermatitis, is under FDA review. Barrier has other product candidates in various stages of clinical development for the treatment of onychomycosis, lamellar ichthyosis, acne, psoriasis and fungal infections. The Company is headquartered in Princeton, New Jersey and has wholly owned subsidiaries in Geel, Belgium and Ontario, Canada. Web site:

Contact Information

  • Contact:
    Barrier Therapeutics, Inc.
    Anne M. VanLent

    Noonan Russo
    Jane Petrino